42% lower risk of death! The team of Ye Dingwei of Fudan University released the first Chinese plan for the treatment of metastatic hormone-sensitive prostate cancer

On September 5, 2022, the team of Ye Dingwei of the Department of Urology of the Affiliated Cancer Hospital of Fudan University published a research paper in the journal Lancet Oncology, which lasted more than 4 years, comparing the efficacy and safety of "revirutrum combined castration therapy" and the classic "bicalutamide combined castration therapy" in patients with high tumor load metastatic hormone-sensitive prostate cancer, confirming the first new second-generation anti-male drug "revirutamine" independently developed by China.

This article is the original of translational medicine network, please indicate the source when reprinting

Author: Jevin

The dilemma of prostate cancer treatment needs to be solved urgently

 01 

Prostate cancer is a malignant tumor with a very high incidence, ranking second in the world in the incidence of malignant tumors in men, after lung cancer

The treatment effect of early prostate cancer is good, and recently the Affiliated Cancer Hospital of Fudan University released 6,000 cases of early prostate cancer efficacy data, Professor Ye Dingwei said: "The 5-year survival rate of early patients is nearly 100%.

Significant effect of the "Chinese Protocol" for the treatment of prostate cancer

 02 

At present, the general prostate cancer treatment options are mostly based on research in developed countries in

Professor Ye Dingwei's delegation targeted the drug "Reverrumide", a new androgen receptor inhibitor with independent intellectual property rights in China, which has made important innovations and improvements in molecular structure and is more suitable for Chinese prostate cancer populations

The results of the study showed that compared with the bicalutamide group, the risk of imaging progression or death in the revruminate group was reduced by 56%, and the survival time of the patients was significantly longer, and the risk of death was reduced by 42%; Patients in the revirutamide group also showed significant benefits at secondary and exploratory efficacy endpoints; In addition, the Riviruamine group also showed excellent safety.

Professor Ye Dingwei said: "Compared with the classic protocol, patients have a longer survival time and higher drug safety, which means that there is a new Chinese solution for

Innovative drug development will bring new hope to more terminal patients

 03 

"In the public perception, there is often a misunderstanding of drug clinical research, worried about becoming a guinea pig in new drug research," Professor Ye Dingwei said, "In fact, drug clinical research often brings more choices to patients, so that advanced patients who have lost treatment opportunities can use international cutting-edge drugs, which will also greatly reduce the economic burden on some patients, and will also get more comprehensive attention during medication, and the success of CHART research is a good example

Professor Ye Dingwei has led more than 70 international and domestic multi-center clinical research on new drugs and new technologies for urinary tumors, accounting for 80%

Early detection and early treatment are still the key prerequisites

Resources:

This article is intended to introduce the progress of medical research and cannot be used as a reference for

Testimonials/ Live Events

September 27, 14:00-17:30 Shanghai

Innovative technology to help tumor accurate diagnosis and treatment summit forum

Scan the code to participate for free

November 03-04 09:00-17:30 Shanghai

The 3rd Yangtze River Delta In Vitro Diagnostic Industry Forum

Scan the code to participate for free

November 25-27 09:00-17:30 Shanghai

The 4th Shanghai International Conference on Cancer

Scan the code to participate